Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : PHIL, MERCK Partner to Reach Girls With HPV Vaccine

10/23/2020 | 05:06am EST

A partnership has begun between Public Health Initiative Liberia (PHIL) and MERCK & Co, an American Multinational Pharmaceutical company for the conduct of social mobilization to increase the demand for the Human Papilloma or HPV Vaccine for the prevention of Cervical Cancer. PHIL in fulfillment of the partnership is currently working with the Ministry of Health's Expanded Program on Immunization (EPI) to conduct the social mobilization and community engagement exercises to increase the demand for the HPV vaccine in the country.

Cervical Cancer is caused by the Human Papilloma Virus (HPV) which is the leading cause of cancer found in Liberian women between the ages of 15 to 45-years. Studies found that there are over 100 types of HPV, with at least 14 known to cause cancer. According to WHO, types 16 and 18 are mostly responsible for 70percent of cervical cancer cases in the world.

HPV is the main cause of cervical cancer, which is leading cancer in Liberia women between the ages of 15 and 45. Studies found that there are over 100 types of HPV, with at least 14 known to cause cancer. According to the WHO, types 16 and 18 are mostly responsible for 70 percent of cervical cancer cases.

In November of 2019, the government of Liberia through the Ministry of Health's Expanded Program on Immunization with support from Gavi, the Vaccine Alliance launched the HPV Vaccine as part of the routine immunization services for girls at the age of 9 to prevent Cervical Cancer.

Given that HPV is a sexually transmitted infection, the vaccine is highly effective when administered to children. Currently, the government is prioritizing girls that are nine-years-old.

The vaccination is ongoing at all public and private health facilities in the 15 counties that do offer immunization services and is being administered twice, one after every six months for girls at the age of nine.

The need for the ongoing mobilization and community engagements cannot be overemphasized as the shutdown of schools coupled with the fear of visiting facilities because of COVID-19 among Liberians has affected the demand generation activities around this vaccine.

PHIL executive Director Madam Joyce L. Kilikpo believes that the support from MERCK came at a critical time as all efforts are being made by governments and partners in ensuring important services such as routine immunization is not affected badly due to the COVID19 outbreak as was seen during the Ebola outbreak of 2014-2015.

As was with the lockdown requirement, planned health facility outreach activities and mass campaigns were all suspended as such, the country is seeing a reduction in routine immunization coverage particularly, the HPV Vaccine which was introduced barely 3 months before the Coronavirus outbreak.

"We cannot afford to let the history repeat itself as was with Ebola. With lessons learned from Ebola, our focus is again community engagement for the uptake of routine immunization services - it is at the front and center of what we do during this fight against the COVID-19 pandemic," -Joyce L. Kilikpo, the Executive Director said. She thanked MERCK & Co for the partnership and support.

Merck and Co, also known as Merck Sharp &Dohme (MSD PTY D) outside the US and Canada is one of the largest pharmaceutical companies in the world. The company is providing financial support to PHIL for the social mobilization and community engagement exercise.

About PHIL

Public Health Initiative Liberia (PHIL) was conceived in 2011 by Liberian Health Professionals living in the diaspora to contribute toward the effectiveness of the health care delivery system of Liberia through leadership, partnership, innovation, advocacy and empowerment.

PHIL management team consists of a group of qualified, competent, committed and dedicated Liberians health professionals with a wealth of experiences acquired through working with national and international development organizations including (the Red Cross, International Medical Crops, the World Health Organization, United Nations Children Fund and Medicine Sans Frontier Belgium) in countries like Haiti, Sudan, Pakistan and Liberia among others, they have good understanding on implementing donor funded projects (USAID, European Union and Global fund).

Despite the relative success of the 2007-11 National Health Plan, Liberia continues to have very poor health indicators - especially among women and girls in rural areas - with a heavy burden of infectious disease. PHIL program will address some of these challenges through capacity building of community-based health workers and partnership.

Copyright The New Dawn. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

All news about MERCK & CO., INC.
11/24MERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
11/24CORCEPT THERAPEUTICS INCORPORATED : Appoints Gillian M. Cannon, PhD, to Board of..
11/24MERCK : to Acquire OncoImmune
11/23GLOBAL MARKETS LIVE: Boeing’s 737 Max to resume flights in Europe, Merck’s la..
11/23MERCK : Correction to Merck to Buy OncoImmune Article
11/23Merck to Buy OncoImmune for $425 Million Amid Race for Covid-19 Treatments --..
11/23MERCK : Applies in U.S., Europe to License V114 Pneumococcal Conjugate Vaccine
11/23Merck to Buy OncoImmune Amid Covid-19 Vaccine Development
11/23MERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
11/23MERCK : to Acquire OncoImmune
More news
Financials (USD)
Sales 2020 48 147 M - -
Net income 2020 11 964 M - -
Net Debt 2020 14 612 M - -
P/E ratio 2020 17,0x
Yield 2020 3,04%
Capitalization 203 B 203 B -
EV / Sales 2020 4,51x
EV / Sales 2021 4,17x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 22
Average target price 96,05 $
Last Close Price 80,14 $
Spread / Highest target 33,5%
Spread / Average Target 19,8%
Spread / Lowest Target 6,06%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-11.89%202 757
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-3.77%283 004
PFIZER INC.-6.59%202 993
NOVARTIS AG-13.38%198 168
ABBVIE INC.15.41%180 396